Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

30.57
+1.043.52%
Post-market: 30.700.1300+0.43%19:57 EST
Volume:2.36M
Turnover:71.91M
Market Cap:4.85B
PE:11.01
High:30.95
Open:29.54
Low:29.29
Close:29.53
52wk High:46.48
52wk Low:25.28
Shares:158.76M
Float Shares:148.00M
Volume Ratio:2.29
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):0.1500
ROE:111.96%
ROA:7.97%
PB:7.99
PE(LYR):203.80

Loading ...

TG Therapeutics Inc. Updates Financial Calendar

Reuters
·
Yesterday

Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release

Simply Wall St.
·
Feb 20

TG Therapeutics Reports Five-Year BRIUMVI Data Showing Sustained Efficacy in Relapsing MS

Reuters
·
Feb 17

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

GlobeNewswire
·
Feb 17

TG Therapeutics Partners with Christina Applegate to Launch Multiple Sclerosis Awareness Campaign

Reuters
·
Feb 09

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

BUZZ-TG Therapeutics rises on new data for autoimmune therapy

Reuters
·
Feb 06

TG Therapeutics startet Phase-3-Studie zu Ublituximab bei Kindern und Jugendlichen mit Multipler Sklerose

Reuters
·
Feb 06

TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum

Reuters
·
Feb 06

TG Therapeutics Announces Presentation of Data for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Feb 06

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

TG Therapeutics Unveils New BRIUMVI Data in Multiple Sclerosis at ACTRIMS 2026

Reuters
·
Jan 28

TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Jan 27

Stock Track | TG Therapeutics Soars 5.01% Intraday on High Growth Projections and Upside Potential

Stock Track
·
Jan 16

These under-the-radar stocks combine fast growth with big upside potential

Dow Jones
·
Jan 15

TG Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jan 15

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

TIPRANKS
·
Jan 15

TG Therapeutics Shares Hit Highest Since November, Last up 12.9% After Prelim 2025 Sales Top Estimate

THOMSON REUTERS
·
Jan 14

Unusually active option classes on open January 14th

TIPRANKS
·
Jan 14